Dennis Carney

Substantial Susceptibility of Chronic Lymphocytic Leukemia to BCL2 Inhibition: Results of a Phase I Study of Navitoclax in Patients With Relapsed or Refractory Disease

Andrew W. Roberts, John F. Seymour, Jennifer R. Brown et al. · Journal of Clinical Oncology · 2011 · 818 citations · Full text

Medicine, Pharmacokinetics, Pharmacology +13

A multicentre retrospective comparison of central nervous system prophylaxis strategies among patients with high-risk diffuse large B-cell lymphoma

Chan Y. Cheah, Kirsten Herbert, Kacey O’Rourke et al. · British Journal of Cancer · 2014 · 132 citations · Full text

Medicine, Oncology, Pharmacotherapy +16

Therapy-related myelodysplastic syndrome and acute myeloid leukemia following fludarabine combination chemotherapy

Dennis Carney, David Westerman, Constantine S. Tam et al. · Leukemia · 2010 · 106 citations

Medicine, Hematology, Oncology +16

OSW-1: a Natural Compound With Potent Anticancer Activity and a Novel Mechanism of Action

Yan Zhou, Celia Garcı́a-Prieto, Dennis Carney et al. · JNCI Journal of the National Cancer Institute · 2005 · 103 citations

Medicine, Oncology, Pharmacology +13

Phase 1 study of the safety, pharmacokinetics, and antitumour activity of the <scp>BCL</scp>2 inhibitor navitoclax in combination with rituximab in patients with relapsed or refractory <scp>CD</scp>20⁺ lymphoid malignancies

Andrew W. Roberts, Ranjana H. Advani, Brad S. Kahl et al. · British Journal of Haematology · 2015 · 99 citations · Full text

Pharmacy, Pharmacokinetics, Pharmacology +17